Ark Invest analyst says these are two of the firm's favorite genomic revolution plays
April 12, 2021 at 18:29 PM EDT
In a CNBC interview, Ark Invest analyst Simon Barnett explains the firm's belief in Adaptive Biotechnologies and Invitae.